Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin in Metastatic Colorectal Cancer Carcinoma An Open-label Phase II

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Dec 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aspirin (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Regorafenib (Primary)
Indications Carcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms REPROGRAM-01

21 Dec 2023 Status changed from active, no longer recruiting to completed.
01 Jul 2023 Results presented at the 25th World Congress on Gastrointestinal Cancer
09 Feb 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com